#1 Clinical Trials Search in Europe

Risedronate Sodium

This article examines clinical trials investigating the use of Risedronate Sodium, a medication commonly known as Actonel, in treating conditions like osteoporosis and Paget’s disease of bone. These studies aim to evaluate the drug’s effectiveness, safety, and patient satisfaction across different dosing regimens and patient populations.

Table of Contents

What is Risedronate Sodium?

Risedronate Sodium is a medication that belongs to a class of drugs called bisphosphonates. It is commonly known by its brand names Actonel and Benet[1]. This medication is primarily used to treat and prevent certain bone conditions, particularly those related to reduced bone density[2].

What Conditions Does Risedronate Sodium Treat?

Risedronate Sodium is used to treat several conditions related to bone health:

  • Postmenopausal Osteoporosis: This is a condition where bones become weak and brittle after menopause, increasing the risk of fractures[3].
  • Osseous Paget’s Disease: A chronic disorder that can result in enlarged and misshapen bones[1].
  • Glucocorticoid-Induced Osteoporosis (GIO): This is bone loss caused by long-term use of steroid medications[4].
  • Prevention of Bone Loss in Cancer Patients: Specifically in patients receiving high-dose corticosteroids for the treatment of acute lymphocytic leukemia (ALL) and lymphoblastic lymphoma (LL)[5].

How Does Risedronate Sodium Work?

Risedronate Sodium works by slowing down bone loss in your body. It helps to maintain or increase bone density and reduces the risk of fractures. The medication does this by:

  • Inhibiting bone breakdown (resorption)
  • Promoting bone formation
  • Improving bone mineral density (BMD)

These effects are measured through various bone turnover markers, which are substances in the blood or urine that indicate the rate of bone formation and breakdown[6].

Dosage Forms and Administration

Risedronate Sodium comes in different dosage forms and strengths:

  • 5 mg tablets taken daily[3]
  • 35 mg tablets taken once a week[7]
  • 75 mg tablets taken once a month[8]
  • 150 mg tablets taken once a month[2]

The medication should be taken with a full glass of water (about 180 mL) on an empty stomach, at least 30 minutes before the first food, drink, or other medication of the day. Patients should remain upright (sitting or standing) for at least 30 minutes after taking the medication to reduce the risk of esophageal irritation[8].

Effectiveness of Risedronate Sodium

Clinical trials have shown that Risedronate Sodium is effective in:

  • Increasing bone mineral density (BMD) in various parts of the body, including the lumbar spine, femur neck, and total hip[6]
  • Reducing the risk of new vertebral and non-vertebral fractures[6]
  • Improving bone turnover markers, indicating a positive effect on bone metabolism[8]

Potential Side Effects and Safety

While Risedronate Sodium is generally well-tolerated, it can cause some side effects. Common side effects may include:

  • Gastrointestinal issues (such as stomach pain, nausea, or diarrhea)
  • Muscle and joint pain
  • Headache

Rare but serious side effects can include osteonecrosis of the jaw (a severe bone disease affecting the jaw) and atypical femur fractures. It’s important to discuss any concerns or unusual symptoms with your healthcare provider[1].

Patient Satisfaction and Compliance

Studies have been conducted to assess patient satisfaction and compliance with different dosing regimens of Risedronate Sodium. Some patients may prefer the once-weekly or once-monthly dosing options over daily dosing, as it may be more convenient and improve adherence to the medication regimen[7].

Monitoring During Treatment

During treatment with Risedronate Sodium, your healthcare provider may monitor several aspects of your health:

  • Bone Mineral Density (BMD): Usually measured by dual-energy X-ray absorptiometry (DXA) scans
  • Bone Turnover Markers: Blood and urine tests to measure substances that indicate bone formation and breakdown
  • Height Measurements: To monitor for potential height loss due to vertebral fractures
  • Calcium and Vitamin D Levels: As these nutrients are crucial for bone health

Regular follow-ups and these monitoring tests help ensure the medication is working effectively and safely[6][8].

Aspect Details
Primary Conditions Studied Osteoporosis (postmenopausal), Paget’s disease of bone
Dosing Regimens 5 mg daily, 35 mg weekly, 75 mg monthly, 17.5 mg daily (Paget’s disease)
Key Efficacy Measures Changes in BMD, fracture rates, bone turnover markers
Safety Assessments Adverse drug reactions, long-term effects, gastrointestinal tolerability
Patient-Centered Outcomes Satisfaction with dosing regimens, treatment compliance and persistence
Special Populations Postmenopausal women, patients on corticosteroid therapy
Imaging Techniques DXA, QCT for bone density and quality assessment
Biomarkers Studied P1NP, CTX, NTX, BAP, TRACP-5b
Duration of Studies Ranging from 12 weeks to 36 months
Comparative Studies Risedronate vs. Alendronate, different dosing schedules of Risedronate

FAQ

  • What conditions is Risedronate Sodium used to treat in these clinical trials? Risedronate Sodium is primarily studied for treating osteoporosis, especially in postmenopausal women, and Paget's disease of bone. Some trials also look at its use in preventing bone loss in patients receiving high-dose corticosteroids for conditions like leukemia and lymphoma.
  • What are the different dosing regimens of Risedronate Sodium explored in these trials? The trials explore various dosing regimens, including 5 mg daily, 35 mg once a week, 75 mg once monthly, and 17.5 mg daily for specific conditions like Paget's disease. The studies compare these different dosing schedules to assess effectiveness and patient satisfaction.
  • How is the effectiveness of Risedronate Sodium measured in these trials? Effectiveness is measured through various means, including changes in bone mineral density (BMD), reduction in fracture rates, changes in bone turnover markers like serum NTX and BAP, and improvements in bone quality parameters assessed by imaging techniques like DXA and QCT.
  • What are some of the safety aspects being evaluated in these trials? The trials assess the safety of Risedronate Sodium by monitoring adverse drug reactions, evaluating long-term use effects, and examining specific concerns like gastrointestinal tolerability. Some studies also look at the drug's safety in special populations, such as patients on corticosteroid therapy.
  • How do these trials consider patient experience and satisfaction? Several trials focus on patient satisfaction and compliance, comparing different dosing regimens (e.g., daily vs. weekly) to see which is preferred. They use questionnaires and medication adherence measures to assess how dosing frequency affects patient satisfaction and treatment persistence.

Ongoing Clinical Trials on Risedronate Sodium

  • Study of Risedronate Sodium for Patients with Dilated Cardiomyopathy Due to Troponin T Gene Mutation

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study on Treating Osteogenesis Imperfecta in Patients Using Teriparatide and Zoledronic Acid

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark France Ireland The Netherlands

Glossary

  • Bone Mineral Density (BMD): A measure of bone strength and health, typically assessed using specialized X-ray techniques. Higher BMD indicates stronger bones.
  • Osteoporosis: A condition characterized by decreased bone mass and increased risk of fractures, often occurring in postmenopausal women.
  • Paget's Disease of Bone: A chronic disorder that typically results in enlarged and deformed bones due to excessive breakdown and formation of bone tissue.
  • Dual-energy X-ray Absorptiometry (DXA): An imaging technique used to measure bone density and assess the risk of osteoporosis and fractures.
  • Bone Turnover Markers: Biochemical markers in blood or urine that indicate the rate of bone formation and breakdown, used to monitor bone metabolism and treatment effectiveness.
  • N-terminal Propeptide of Type I Collagen (P1NP): A marker of bone formation used to assess the effectiveness of osteoporosis treatments.
  • Adverse Drug Reaction (ADR): An unwanted or harmful reaction experienced following the administration of a drug or combination of drugs.
  • Glucocorticoid-Induced Osteoporosis (GIO): A form of osteoporosis caused by long-term use of glucocorticoid medications, often used to treat inflammatory conditions.
  • Quantitative Computed Tomography (QCT): An advanced imaging technique that provides detailed 3D images of bone structure and can measure bone density.
  • Treatment Persistence: The duration of time from initiation to discontinuation of therapy, often used to assess how well patients adhere to a prescribed treatment regimen.

References

  1. https://clinicaltrials.gov/study/NCT02106455
  2. https://clinicaltrials.gov/study/NCT00351091
  3. https://clinicaltrials.gov/study/NCT00453492
  4. https://clinicaltrials.gov/study/NCT00616694
  5. https://clinicaltrials.gov/study/NCT00452439
  6. https://clinicaltrials.gov/study/NCT02106442
  7. https://clinicaltrials.gov/study/NCT00549965
  8. https://clinicaltrials.gov/study/NCT02089997